Following the rise of the COVID-19 pandemic, we have focused all our efforts on diagnostic of the SARS-CoV-2 virus responsible for the COVID-19 infection.
Coronaviruses are a large family of single-stranded RNA viruses that infect mammals and birds, causing respiratory infection. More specifically, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS coronavirus 2 or SARS-CoV-2), a virus closely related to the SARS virus, causes the infectious disease named COVID-19 (novel Coronavirus disease 2019).
The novel coronavirus was first isolated from patients with pneumonia, connected to the cluster of acute respiratory illness cases from Wuhan, China. Genetic analysis revealed its close relation to SARS-CoV and genetic clusters within the genus Betacoronavirus, forming a distinct clade in lineage B of the subgenus Sarbecovirus together with two bat-derived SARS-like strains.
Thanks to our internal expertise on molecular diagnostic solutions for infectious diseases, we have been able to bring tests rapidly to the market. We are very proud to participate in the fight against this pandemic with two molecular diagnostic tests (now CE-IVD).
Since December 2019, COVID-19 has been spreading rapidly throughout the World. You can follow live evolution of the infection on the WHO Coronavirus Disease (COVID-19) Dashboard.
Gastrointestinal infections (GI infections) are caused by viral, bacterial or parasitic microorganisms. They are the source of gastroenteritis and inflammation of gastrointestinal tract, symptoms of which include abdominal pain, vomiting and diarrhea often leading to potentially dangerous dehydration.
In the case of gastrointestinal infections, typical bacterial pathogens include E. coli, Salmonella, Shigella and Campylobacter. Additionally, norovirus, rotavirus and adenovirus are most likely to cause viral infections. While parasitic infections can stem from a variety of pathogens like Giardia lamblia and Cryptosporidium spp.
In most cases, gastrointestinal infections often resolve themselves in a few days without any treatment. However, diagnosis through laboratory tests may be needed in certain cases, for example in healthcare settings when symptoms persist past a reasonable time or in specific patient populations.
Antimicrobial Resistance Management
Antimicrobial resistance (AMR) is a significant and growing global health challenge. Due to the excessive use of antibiotics across the world, the number of multidrug resistant organisms, also called “super bacteria”, have been increasing and making antibiotics less and less effective.
Beta-lactams are by far the most used antibiotics worldwide. They include carbapenems which are the most effective against Gram-positive and Gram-negative bacteria. However, during the last decade, Gram-negative bacilli (in particular Enterobacteriaceae) with a decreased susceptibility to carbapenems have been increasingly reported worldwide. Also there is a growing resistance to “last resort” antibiotics such as vancomycin and colistin. As result, a simple infection can result in a therapeutic dead-end.
For these reasons, fast diagnosis is key in treating patients with AMR infections. Rapid detection of pathogens and their potential resistance to antibiotics enable implementation of faster infection control practices, decrease the risk of infection spreading and reduces healthcare costs. Indeed, molecular diagnostics offer a much faster method for the diagnosis of AMR, and more extensive screening capabilities.
Learn more about the current recommendations on tackling drug-resistant infections globally.
Nosocomial infections, also called healthcare-associated infections or hospital-acquired infections (HAIs), are infections patients acquire in a hospital or other healthcare facility.
The most common types of HAIs include infections following surgeries, urinary tract infections and lower respiratory tract infections. For example, bacterial pathogens like Clostridium difficile, Enterobacteriaceae or Staphylococcus aureus are generally responsible for hospital-associated infections.
Overall, hospital-acquired infections occur both in developed and developing countries. According to the World Health Organization, they are among the prime causes of death and increased morbidity among hospitalized patients. Moreover, the economic costs of HAIs are substantial. As a matter of fact, the prolonged hospital stay they necessitate - together with patient increasing use of medication and their need for isolation - can lead to considerable costs to patients or healthcare payers.
Sepsis is a potentially life-threatening condition caused by the body's response to an infection. It can lead to septic shock, multiple organ failure and death. For these reasons, early detection of sepsis is critical in improving patients’ chances of survival. Currently, sepsis represents a major global health concern affecting more than 30 million people worldwide every year and is responsible for up to 6 million deaths every year(1). It is usually treated with antibiotics and large amounts of intravenous fluids.
Supported by Business Finland and thanks to Mobidiag's internal expertise on molecular diagnostic solutions for infectious diseases, we are developing a revolutionary assay to detect sepsis causing microbes and antibiotic resistances. Mobidiag is harnessing the power of its Novodiag® platform to develop a fast, simple and reliable syndromic assay. It will allow sepsis detection within a couple of hours, directly from a patient’s blood sample. Mobidiag has previous experience in developing diagnostic tests for sepsis with its former Prove-it product allowing to detect 80 targets simultaneously from blood cultures (product now discontinued).
Learn more about our latest announcement and development regarding sepsis.